ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Sjogren’s syndrome"

  • Abstract Number: 2799 • 2015 ACR/ARHP Annual Meeting

    Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE

    Eliza F. Chakarvarty1, Jacy Odell2, Astrid Rasmussen3, Kathy L. Sivils2, Joel M. Guthridge2 and Judith A. James4, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, 2Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: Increasing data has suggested that individuals with systemic lupus (SLE) are at increased risk of herpes zoster (HZ) reactivation compared to healthy controls and…
  • Abstract Number: 621 • 2015 ACR/ARHP Annual Meeting

    Previous Diagnosis of Sjögren’s Syndrome As Rheumatoid Arthritis or Systemic Lupus Erythematosus

    Astrid Rasmussen1, Lida Radfar2, Kiely Grundahl3, David M. Lewis4, Donald U Stone5,6, C. Erick Kaufman7, Daniel J Wallace8, Michael H. Weisman9, Swamy Venuturupalli10, Christopher J Lessard11, Biji Kurien12, Juan-Manuel Anaya13, Michael D. Rohrer14, Raj Gopalakrishnan15, Glen D Houston16, James Chodosh17, Pamela J Hughes18, Nelson L. Rhodus19, John Ice1, Kimberly Hefner20, Jennifer A. Kelly21, Kathy L. Sivils1 and R. Hal Scofield1,22,23, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oral Diagnosis and Radiology Department, University of Oklahoma Health Sciences Center College of Dentistry, Oklahoma City, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 4College of Dentistry, Department of Oral and Maxillofacial Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 5Department of Ophthalmology, Johns Hopkins University, Riyadh, Saudi Arabia, 6Research Department, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, 7College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 8Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 9Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 10Cedars-Sinai Medical Center, West Hollywood, CA, 11Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 13Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, 14Hard Tissue Research Laboratory, University of Minnesota School of Dentistry, Minneapolis, MN, 15Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota, Minneapolis, MN, 16Heartland Pathology, Oklahoma City, OK, 17Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, 18Division of Oral and Maxillofacial Surgery, University of Minnesota, Minneapolis, MN, 19Department of Oral Surgery, University of Minnesota School of Dentistry, Minneapolis, MN, 20Hefner Eye Care and Optical Center, Oklahoma City, OK, 21Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 22Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 23US Department of Veterans Affairs Medical Center, Oklahoma City, OK

    Background/Purpose: The diagnosis of Sjögren′s Syndrome (SS) is often difficult and many patients are symptomatic for years with other diagnoses before confirmation of SS. Overlapping…
  • Abstract Number: 639 • 2015 ACR/ARHP Annual Meeting

    Association Between Insomnia and EULAR Sjögren’s Syndrome Patient-Reported Index in Korean Patients with Primary Sjögren’s Syndrome

    Jaehyung Hur1, Sang Wan Chung1, You Jung Ha2, Eun Ha Kang3, Yeong Wook Song4 and Yun Jong Lee5, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, 2Division of Rheumatology, Department of Internal Medicine,Seoul National University Bundang Hospital, Seongnam, South Korea, 3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, 5Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea

    Background/Purpose: EULAR Sjögren's syndrome Patient-Reported Index (ESSPRI) is an index to evaluate symptom severity and recommended as an efficacy measure for clinical trials in primary…
  • Abstract Number: 1776 • 2015 ACR/ARHP Annual Meeting

    Significantly Reduced Lymphadenopathy, Salivary Gland Infiltrates and Proteinuria in MRL-Lpr/Lpr Mice Treated with Ultrasoluble Curcumin/Turmeric: Increased Survival with Curcumin Treatment

    Biji T Kurien1,2,3, Valerie M Harris1,4, Syed MS Quadri1,4, Patricia Coutinho-de Souza1, Joshua Cavett5,6, Amanda Moyer4, Bilal Ittiq7, Angela Metcalf6, Husayn Ramji8, Dat Truong8, Kristi A. Koelsch4,9,10, Mike Centola11, Adam Payne12, D. Danda13 and R. Hal Scofield1,14, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4University of Oklahoma Health Sciences Center, Oklahoma City, OK, 5Allergy and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 7University of Oklahoma Health Sciences Center, Oklahoma, OK, 8University of Oklahoma, Oklahoma City, OK, 9Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, 10Department Veterans Affairs Medical Center, Oklahoma City, OK, 11Haus Bioceuticals, Oklahoma City, OK, 12Arthritis and Immunology, Oklahoma Medical Research Foun, Oklahoma City, OK, 13Christian Medical College, Vellore, India, 14US Department of Veterans Affairs Medical Center, Oklahoma City, OK

    Background/Purpose: Commercial curcumin (CU), derived from food spice turmeric, has been widely studied as a potential therapeutic for a variety of oncological and inflammatory conditions.…
  • Abstract Number: 2800 • 2015 ACR/ARHP Annual Meeting

    Bone Microarchitecture and Bone Strength in Patients with Primary Sjögren’s Syndrome: A Case-Control Study Using HR-pQCT

    Sandra Gofinet Pasoto1, Kristopherson Lustosa Augusto1, Jackeline Couto Alvarenga2, Liliam Takayama1, Valéria Caparbo3, Ricardo M. Oliveira4, Eloisa Bonfá1 and Rosa M R Pereira1, 1Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4RDO Diagnósticos Médicos, São Paulo, Brazil

    Background/Purpose: To evaluate bone mineral density (BMD), microarchitecture, strength and prevalence of vertebral fractures (VF) in primary Sjögren's syndrome (pSS).Methods: We evaluated 71 female pSS…
  • Abstract Number: 622 • 2015 ACR/ARHP Annual Meeting

    Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Dry Eyes

    Frederick B Vivino1, Gary Foulks2, S. Lance Forstot3, Peter Donshik4, Joseph Forstot5, Michael Goldstein6, Michael Lemp7, J. Daniel Nelson8,9, Kelly K. Nichols10,11, Stephen C. Pflugfelder12, Jason Tanzer13, Penny Asbell14, Deborah S. Jacobs15,16, Katherine M Hammitt17 and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, 1University of Pennsylvania, Philadelphia, PA, 2Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY, 3Corneal Consultants of Colorado, Littleton, CO, 4Department of Ophthalmology, University of Connecticut Health Center, Farmington, CT, 5Rheumatology Associates of South Florida, Boca Raton, FL, 6New England Eye Center, Tufts Medical Center, Boston, MA, 7Department of Ophthalmology, Georgetown University, Washington, DC, 8Ophthalmology, HealthPartners Specialty Center, St. Paul, MN, 9Dept. of Ophthalmology, University of Minnesota, St. Paul, MN, 10School of Optometry, The University of Alabama at Birmingham, Birmingham, AL, 11College of Optometry, (formerly) University of Houston, Houston, TX, 12Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, TX, 13Department of Oral Health and Diagnostic Sciences, University of Connecticut School of Dental Medicine, Farmington, CT, 14Dept of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, 15Boston Foundation for Sight, Needham, MA, 16Cornea and External Diseases, Massachusetts Eye and Ear, Boston, MA, 17Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD

    Background/Purpose: Dry eyes can compromise quality of life in Sjogren’s Syndrome (SS) and is often one of the most troublesome symptoms.  Clinical practice guidelines were…
  • Abstract Number: 641 • 2015 ACR/ARHP Annual Meeting

    Pain, Xerostomia and Younger Age Are Major Determinants of Fatigue in Korean Primary Sjögren’s Syndrome Patients: A Comprehensive Analysis of a Cohort Study

    JungHee Koh1, Seung-Ki Kwok2, Min Kyung Chung3, Jennifer Lee3, Ji Yeon Lee4 and Sung-Hwan Park3, 1Seochogu, Banpodaero, 222, Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, 2[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: Fatigue is a common clinical manifestation in patients with primary Sjögren¡¯s syndrome (PSS). The aims of this study were to investigate the association between…
  • Abstract Number: 1871 • 2015 ACR/ARHP Annual Meeting

    Familial Aggregation of Rheumatoid Arthritis, Sjögren’s Syndrome, and Systemic Sclerosis Were Detected in Systemic Lupus Erythematous Families

    Rufei Lu1, Hua Chen1, Krista Bean1, Teresa Aberle1, Joel Guthridge1 and Judith James1,2, 1Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Medicine & Pathology, Univ. of Oklahoma, Okla, OK

    Background/Purpose: Many systemic autoimmune diseases share heritable and non-heritable risks, as well as some clinical manifestations. A recent meta-analysis based upon genome-wide genetic studies contrasting…
  • Abstract Number: 2801 • 2015 ACR/ARHP Annual Meeting

    Tofacitinib Suppresses Lymphocytic Infiltration in the Salivary Gland of Non-Obese Diabetic Mice; The Animal Model of Sjögren’s Syndrome

    Jennifer Lee1, Ji Yeon Lee2, Jung Hee Koh3, Min Kyung Chung4, Ji Hun Kim1, Seung-Ki Kwok5, Ji Hyeon Ju2 and Sung-Hwan Park6, 1Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, 4Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea, 5[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 6Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, South Korea

    Background/Purpose: Interferon signatures are upregulated in patients with primary Sjogren’s syndrome (pSS) and interferons are considered to have a pathogenic role in pSS. As Janus…
  • Abstract Number: 2551 • 2014 ACR/ARHP Annual Meeting

    Presence of Germinal Centers at Baseline Is Associated with Clinical Response of Glandular Essdai Domain after Abatacept Treatment in Primary Sjogren’s Syndrome

    Erlin A. Haacke1, Frans G.M. Kroese2, Petra M. Meiners3, Bert van der Vegt1, Arjan Vissink4, Fred K.L. Spijkervet3 and Hendrika Bootsma2, 1Pathology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 3Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 4Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands

    Background/Purpose: Abatacept inhibits the costimulatory interaction of T-lymphocytes and antigen-presenting cells. Treatment of early and active primary Sjögren's Syndrome (pSS) with abatacept decreases disease activity.…
  • Abstract Number: 985 • 2014 ACR/ARHP Annual Meeting

    Labial Salivary Gland Antibody-Secreting Cell Specificity and Characteristics in Sjögren’s Patients

    Kristi A. Koelsch1, Jacen Maier-Moore2, Kenneth Smith3, Christopher Lessard3, Astrid Rasmussen4, Biji Kurien3, Umesh Deshmukh3, A. Darise Farris3, Judith A. James5, Kathy L. Sivils4, R. Hal Scofield6 and Mark Coggeshall7, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, 2Dept. of Clinical Laboratory Science, University of Texas at El Paso, El Paso, TX, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 7Immunobiology and Cancer Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose Studies were approved by the OMRF and the University of Oklahoma Health Sciences Center Institutional Review Boards. Samples and data were obtained from 9…
  • Abstract Number: 2977 • 2014 ACR/ARHP Annual Meeting

    Distinct Serum Protein Signature and Novel Biomarkers of primary Sjogren’s Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis

    Ayumi Nishikawa1, Katsuya Suzuki2, Yoshiaki Kassai3, Yuumi Gotou4, Takahiro Miyazaki3, Maiko Takiguchi5, Masaru Takeshita1, Atsuko Murota2, Rimpei Morita6, Akihiko Yoshimura6 and Tsutomu Takeuchi2, 1Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, 4Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, 5Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Japan, 6Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: The EULAR SS Disease Activity Index (ESSDAI) is currently used as an objective evaluation method of clinical disease activity in clinical research into primary…
  • Abstract Number: 2550 • 2014 ACR/ARHP Annual Meeting

    Impaired Speckle Tracking As a Marker of Subclinical Left Ventricular Dysfunction in Patients Affected By Primary Sjögren’s Syndrome

    Fabiola Atzeni1, Stefano Galaverna2, Chiara Colombo2, Luigi Gianturco2, Laura Boccassini1, Piercarlo Sarzi-Puttini1 and Maurizio Turiel2, 1Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, 2Cardiology Unit, IRCCS-Galeazzi Orthopedic Institute,, Milan, Italy

    Background/Purpose Primary Sjögren’s syndrome (pSS) is a common chronic autoimmune disease that particularly affects the salivary and lachrymal glands, and leads to dry eyes and…
  • Abstract Number: 534 • 2014 ACR/ARHP Annual Meeting

    Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of  Anti-Ro Associated Congenital Heart Block

    Amit Saxena1, Peter M. Izmirly2, Sung Won Han3, Andrew Markham4, Robert M. Clancy5 and Jill P. Buyon5, 1Rheumatology, New York University School of Medicine, New York, NY, 2Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3Department of Population Health, New York University School of Medicine, New York, NY, 4Medicine, New York University School of Medicine, New York, NY, 5Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY

    Background/Purpose Women with Sjogren’s Syndrome (SS) and anti-Ro antibodies face the risk of a pregnancy complicated by fetal congenital heart block (CHB).  Identification of maternal…
  • Abstract Number: 2979 • 2014 ACR/ARHP Annual Meeting

    Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5 Collaborate in Driving the Systemic IFN Signature and Amplify the Pathogenic Loop: Potential New Targets for Therapy in Primary Sjogrens Syndrome

    Naomi I Maria1, Cornelia G. van Helden-Meeuwsen1, Eline C. Steenwijk1, Arne S. IJpma2, Wouter Beumer1, Zana Brkic1, Virgil A. Dalm1, Paul L. van Daele1, P. Martin van Hagen1, Peter J. van der Spek2, Hemmo A. Drexhage1 and Marjan A. Versnel1, 1Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 2Erasmus Medical Center, Bioinformatics, Rotterdam, Netherlands

    Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by autoantibodies targeting RNA-associated antigens, anti-SSA/SSB. The IFN-signature is present in over half of…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 26
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology